← Eichor
Study identifier: NCT06301438 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Dalpiciclib in HR+/HER2- ABC

Condition: Advanced Breast Cancer  ·  Sponsor: RenJi Hospital

PhaseN/A
Planned participants103
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Wenjin Yin  ·  86(21)68385569  ·  yinwenjin@renji.com

Always discuss trial participation with your own doctor first.

Locations (1)

Renji Hospital, School of Medicine, Shanghai Jiaotong UniversityShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06301438